STAT3 and neoplasm: IDO expression can be blocked by inhibitors of c-KIT or mTOR (downstream of the c-KIT/PI3K/AKT pathway), with resultant enhancement of anti-tumor T cell responses [31], but the potential role of PI3K/AKT/CREB signaling or STAT3 activation has not been addressed.